Skip to main content

ADAM17 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 5 and 2 bp deletion in exon 5.

Be the first to review this product! Submit a review

Images

Western blot - Human ADAM17 knockout HeLa cell lysate (AB256829), expandable thumbnail
  • Sanger Sequencing - Human ADAM17 knockout HeLa cell lysate (AB256829), expandable thumbnail
  • Sanger Sequencing - Human ADAM17 knockout HeLa cell lysate (AB256829), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Knockout validation
Sanger Sequencing
Mutation description
Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 5 and 2 bp deletion in exon 5.

Alternative names

A disintegrin and metalloproteinase domain 17, A disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme), ADA17_HUMAN, ADAM 17, ADAM metallopeptidase domain 17, ADAM17 protein, CD 156b, CD156b antigen, CSVP, Disintegrin and metalloproteinase domain-containing protein 17, MGC71942, NISBD, NISBD1, Snake venom-like protease, TACE, TNF-alpha convertase, TNF-alpha-converting enzyme, Tumor Necrosis Factor Alpha Converting Enzyme

What's included?

1 Kit
Components
Human ADAM17 knockout HeLa cell lysate
1 x 100 µg
Human wild-type HeLa cell lysate
1 x 100 µg

Recommended products

ADAM17 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 5 and 2 bp deletion in exon 5.

Key facts

Cell type
HeLa
Mutation description
Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 5 and 2 bp deletion in exon 5.
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
ADAM17
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Notes


Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

ADAM17 also known as TACE (tumor necrosis factor-alpha converting enzyme) is a metalloprotease belonging to the ADAM (a disintegrin and metalloprotease) family. This protein functions by cleaving and shedding extracellular portions of cell surface proteins. It weighs approximately 93 kDa. ADAM17 is expressed in a range of tissues including the heart liver kidney and brain. The protein plays a role in the regulation of various biological processes through the activation and inactivation of membrane-bound precursor proteins.

Biological function summary

The ADAM17 protein regulates a multitude of cellular responses such as inflammation and growth factor signaling. It is not part of a complex but interacts with various substrates in the cell membrane. ADAM17 cleaves precursors to release soluble cytokines and growth factors like tumor necrosis factor-alpha (TNF-alpha) and epidermal growth factor receptor (EGFR) ligands which modulate cell proliferation migration and apoptosis.

Pathways

ADAM17 plays an integral role in both the TNF and EGFR signaling pathways. These pathways are important in maintaining normal cellular homeostasis. ADAM17 interacts with proteins like TNF receptors and ligands of the EGFR family integrating signaling that affects immune response and cell growth. The regulatory function of ADAM17 in these pathways makes it an important target for modulating cellular responses triggered by external stimuli.

Associated diseases and disorders

ADAM17 has significant implications in conditions such as rheumatoid arthritis and cancer. In rheumatoid arthritis the protein's shedding activity influences inflammatory cytokines contributing to the disease’s pathogenesis alongside proteins like TNF-alpha. In cancer ADAM17's ability to release EGFR ligands affects tumor cell proliferation and metastasis with interactions involving EGFR proteins. It is a target of therapeutic interest with research focused on developing inhibitors to manage these diseases effectively.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com